• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Predictive Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    6/11/25 4:06:13 PM ET
    $POAI
    Industrial Specialties
    Health Care
    Get the next $POAI alert in real time by email
    false 0001446159 0001446159 2025-06-09 2025-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    _________________

     

    FORM 8-K

    _________________

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):  June 9, 2025

    _______________________________

     

    Predictive Oncology Inc.

    (Exact name of registrant as specified in its charter)

    _______________________________

     

    Delaware 001-36790 33-1007393
    (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

     

    91 43rd Street, Suite 110

    Pittsburgh, Pennsylvania 15201

    (Address of Principal Executive Offices) (Zip Code)

     

    (412) 432-1500

    (Registrant's telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

    _______________________________

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock, $0.01 par value POAI NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On June 9, 2025, Predictive Oncology Inc. (the “Company”) received a letter (the “Notice) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that because the Company had not regained compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), the Staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Company was unable to complete its previously submitted plan of compliance within the 180-day extension period provided under the Listing Rules.

     

    Unless the Company requested an appeal of the Staff’s determination by June 16, 2025, trading of the Company’s common stock would be suspended at the opening of business on June 18, 2025 and a Form 25-NSE would be filed with the Securities and Exchange Commission (“SEC”), which would remove the Company’s securities from listing and registration on the Nasdaq.

     

    The Company has submitted a hearing request to Nasdaq’s Hearings Panel (the “Panel”), and the Panel has received the Company’s request, to appeal the Staff’s determination, which will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Panel has discretion to take actions as prescribed by Nasdaq Listing Rule 5815(c)(1) including, but not limited to, granting an exception to the continued listing standards for a period not to exceed 180 days from the date of the Notice. However, there can be no assurance that the Company’s request to continue listing will be accepted or that if it is, the Company will be able to maintain compliance with requirements for its continued listing on The Nasdaq Capital Market.

     

    The Company will continue to evaluate all available options to regain compliance with the listing requirements.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements, including statements regarding the Company’s appeal of the delisting determination and its plans to regain compliance with Nasdaq’s continued listing requirements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
         
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Predictive Oncology Inc.
         
         
    Date: June 11, 2025 By:  /s/ Josh Blacher        
        Josh Blacher
        Interim Chief Financial Officer
         

     

     

     

     

    Get the next $POAI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $POAI

    DatePrice TargetRatingAnalyst
    8/19/2024$3.00Buy
    H.C. Wainwright
    6/30/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $POAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Court Denies Renovaro Motion for an Expedited Trial in July

      PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB's request for an expedited, two-day trial in July. The Court reached this decision citing RENB's delay in bringing its action.  POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The Court has scheduled trial for November 12-13, 2025. POAI looks forward to its day in Court. About Predictive On

      5/27/25 8:35:13 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

      LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ:POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following t

      5/22/25 3:12:39 PM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

      LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ:POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following t

      5/22/25 11:05:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $POAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • St. Clair Gregory Sr was granted 3,268 shares, increasing direct ownership by 17% to 22,534 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:48 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Hawryluk Matthew was granted 2,368 shares, increasing direct ownership by 33% to 9,488 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:26 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • Rao Veena was granted 3,268 shares, increasing direct ownership by 56% to 9,117 units (SEC Form 4)

      4 - Predictive Oncology Inc. (0001446159) (Issuer)

      4/12/24 5:26:19 PM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    SEC Filings

    See more
    • Predictive Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Predictive Oncology Inc. (0001446159) (Filer)

      6/11/25 4:06:13 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Predictive Oncology Inc.

      8-K - Predictive Oncology Inc. (0001446159) (Filer)

      6/6/25 4:31:09 PM ET
      $POAI
      Industrial Specialties
      Health Care
    • SEC Form 424B5 filed by Predictive Oncology Inc.

      424B5 - Predictive Oncology Inc. (0001446159) (Filer)

      6/2/25 4:16:45 PM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Predictive Oncology with a new price target

      H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

      8/19/24 6:55:24 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. initiated coverage on Predictive Oncology with a new price target

      HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00

      6/30/21 6:22:58 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Litchfield Hills Research initiated coverage on Predictive Oncology with a new price target

      Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00

      2/1/21 10:17:27 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Leadership Updates

    Live Leadership Updates

    See more
    • AIRNA Appoints Matthew Hawryluk as Chief Business Officer

      AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote

      1/30/25 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Renovaro Issues Shareholder Letter and Provides Corporate Update

      Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for

      1/7/25 9:15:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

      EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas

      6/27/23 8:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Financials

    Live finance-specific insights

    See more
    • Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update

      PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i

      11/13/24 7:00:21 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update

      PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s

      8/14/24 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024

      PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas

      8/7/24 7:00:00 AM ET
      $POAI
      Industrial Specialties
      Health Care

    $POAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Predictive Oncology Inc. (Amendment)

      SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)

      2/11/22 7:50:59 AM ET
      $POAI
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Predictive Oncology Inc. (0001446159) (Subject)

      3/1/21 6:23:16 AM ET
      $POAI
      Industrial Specialties
      Health Care